ATE228361T1 - Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen - Google Patents
Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungenInfo
- Publication number
- ATE228361T1 ATE228361T1 AT97928368T AT97928368T ATE228361T1 AT E228361 T1 ATE228361 T1 AT E228361T1 AT 97928368 T AT97928368 T AT 97928368T AT 97928368 T AT97928368 T AT 97928368T AT E228361 T1 ATE228361 T1 AT E228361T1
- Authority
- AT
- Austria
- Prior art keywords
- reducing
- compounds
- cardiotoxicity
- manganeous
- antitumor drugs
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010048610 Cardiotoxicity Diseases 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 231100000259 cardiotoxicity Toxicity 0.000 title abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 title 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229910052748 manganese Inorganic materials 0.000 abstract 2
- 239000011572 manganese Substances 0.000 abstract 2
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preventing Corrosion Or Incrustation Of Metals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Manufacture And Refinement Of Metals (AREA)
- Semiconductor Lasers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9613182.6A GB9613182D0 (en) | 1996-06-24 | 1996-06-24 | Method |
| PCT/GB1997/001721 WO1997049390A1 (en) | 1996-06-24 | 1997-06-24 | Reduction of cardiotoxicity of an antitumor agent using manganese compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE228361T1 true ATE228361T1 (de) | 2002-12-15 |
Family
ID=10795775
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97928368T ATE228361T1 (de) | 1996-06-24 | 1997-06-24 | Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen |
| AT97928369T ATE225178T1 (de) | 1996-06-24 | 1997-06-24 | Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97928369T ATE225178T1 (de) | 1996-06-24 | 1997-06-24 | Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6258828B1 (enExample) |
| EP (2) | EP0910360B1 (enExample) |
| JP (2) | JP4359651B2 (enExample) |
| CN (2) | CN1228694A (enExample) |
| AT (2) | ATE228361T1 (enExample) |
| AU (2) | AU720570B2 (enExample) |
| BR (1) | BR9709942A (enExample) |
| CA (2) | CA2259150A1 (enExample) |
| DE (2) | DE69717447T2 (enExample) |
| GB (1) | GB9613182D0 (enExample) |
| IL (1) | IL127733A0 (enExample) |
| NO (2) | NO985916L (enExample) |
| NZ (2) | NZ333357A (enExample) |
| WO (2) | WO1997049409A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9727224D0 (en) * | 1997-12-23 | 1998-02-25 | Nycomed Imaging As | Method |
| JP2001527072A (ja) * | 1997-12-23 | 2001-12-25 | ニユコメド・イメージング・アクシエセルカペト | 一酸化窒素を放出するキレート化剤およびその治療上の使用 |
| AU770999C (en) | 1999-10-01 | 2005-04-21 | Ampio Pharmaceuticals, Inc. | Metal-binding compounds and uses therefor |
| US7592304B2 (en) | 1999-10-01 | 2009-09-22 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| US7632803B2 (en) | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| FR2823977B1 (fr) | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| GB0117645D0 (en) * | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
| US20040038904A1 (en) * | 2002-05-21 | 2004-02-26 | Angela Ogden | Method of treating multiple sclerosis |
| FR2863892B1 (fr) * | 2003-12-18 | 2007-05-11 | Univ Paris Descartes | Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux |
| AU2005235455B2 (en) | 2004-04-22 | 2011-01-20 | Jazz Pharmaceuticals Therapeutics, Inc. | Liposomal formulations of anthracycline agents and cytidine analogs |
| HUE042678T2 (hu) | 2005-08-31 | 2019-07-29 | Abraxis Bioscience Llc | Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek |
| AU2008339091B2 (en) | 2007-12-14 | 2014-08-07 | Egetis Therapeutics Ab | Compounds for use in the treatment of cancer |
| JP5868852B2 (ja) * | 2009-07-06 | 2016-02-24 | プレッドファルマ・アーベー | マンガン錯体化合物と非マンガン錯体形態の同化合物の組み合わせを用いる医薬組成物及び治療方法 |
| WO2012154861A2 (en) | 2011-05-09 | 2012-11-15 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| MX2014008247A (es) | 2012-01-05 | 2015-03-09 | Pledpharma Ab | Calmangafodipir, una nueva entidad quimica, y otros complejos de metal mezclados, metodos de preparacion, composiciones y metodos de tratamiento. |
| EP2903610B1 (en) | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| BR112015009963A2 (pt) | 2012-11-02 | 2017-07-11 | Pledpharma Ab | uso de compostos para a preparação de composições farmacêuticas para o tratamento de câncer |
| CA2950926A1 (en) | 2014-06-13 | 2015-12-17 | Mayo Foundation For Medical Education And Research | Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas |
| WO2015195476A1 (en) | 2014-06-16 | 2015-12-23 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| EP3413874A4 (en) | 2016-02-12 | 2020-01-22 | Mayo Foundation for Medical Education and Research | TREATMENTS FOR BLOOD CANCER |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| MX2019002474A (es) | 2016-09-01 | 2019-09-18 | Mayo Found Medical Education & Res | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. |
| JP2019526579A (ja) | 2016-09-01 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | Ｔ細胞癌を標的とする為の方法及び組成物 |
| WO2018048815A1 (en) | 2016-09-06 | 2018-03-15 | Nantibodyfc, Llc | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| RU2019110071A (ru) | 2016-09-06 | 2020-10-08 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Способы лечения злокачественных новообразований, экспрессирующих pd-l1 |
| CN109890422A (zh) | 2016-09-06 | 2019-06-14 | 梅约医学教育与研究基金会 | 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES444380A1 (es) * | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US5223243A (en) * | 1987-05-08 | 1993-06-29 | Salutar, Inc. | Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents |
| US4842845A (en) * | 1987-05-08 | 1989-06-27 | Salutar, Inc. | Radioactive metal chelates for dipyridoxyl phosphate |
| US4935518A (en) * | 1987-05-08 | 1990-06-19 | Salutar, Inc. | Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof |
| US6204259B1 (en) * | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
-
1996
- 1996-06-24 GB GBGB9613182.6A patent/GB9613182D0/en active Pending
-
1997
- 1997-06-24 AT AT97928368T patent/ATE228361T1/de not_active IP Right Cessation
- 1997-06-24 JP JP50255798A patent/JP4359651B2/ja not_active Expired - Lifetime
- 1997-06-24 DE DE69717447T patent/DE69717447T2/de not_active Expired - Lifetime
- 1997-06-24 NZ NZ333357A patent/NZ333357A/xx unknown
- 1997-06-24 AT AT97928369T patent/ATE225178T1/de not_active IP Right Cessation
- 1997-06-24 EP EP97928368A patent/EP0910360B1/en not_active Expired - Lifetime
- 1997-06-24 CA CA002259150A patent/CA2259150A1/en not_active Abandoned
- 1997-06-24 EP EP97928369A patent/EP0936915B1/en not_active Expired - Lifetime
- 1997-06-24 JP JP50255898A patent/JP4162263B2/ja not_active Expired - Lifetime
- 1997-06-24 BR BR9709942A patent/BR9709942A/pt not_active Application Discontinuation
- 1997-06-24 IL IL12773397A patent/IL127733A0/xx unknown
- 1997-06-24 WO PCT/GB1997/001722 patent/WO1997049409A1/en not_active Ceased
- 1997-06-24 AU AU32688/97A patent/AU720570B2/en not_active Ceased
- 1997-06-24 NZ NZ333315A patent/NZ333315A/xx unknown
- 1997-06-24 WO PCT/GB1997/001721 patent/WO1997049390A1/en not_active Ceased
- 1997-06-24 CN CN97197429A patent/CN1228694A/zh active Pending
- 1997-06-24 DE DE69716104T patent/DE69716104T2/de not_active Expired - Lifetime
- 1997-06-24 CA CA002258299A patent/CA2258299A1/en not_active Abandoned
- 1997-06-24 CN CN97197438A patent/CN1228703A/zh active Pending
- 1997-06-24 AU AU32689/97A patent/AU720621B2/en not_active Ceased
-
1998
- 1998-12-17 NO NO985916A patent/NO985916L/no not_active Application Discontinuation
- 1998-12-17 US US09/213,290 patent/US6258828B1/en not_active Expired - Lifetime
- 1998-12-17 NO NO985917A patent/NO985917L/no not_active Application Discontinuation
- 1998-12-17 US US09/213,246 patent/US6147094A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69717447T2 (de) | 2003-09-11 |
| IL127733A0 (en) | 1999-10-28 |
| GB9613182D0 (en) | 1996-08-28 |
| DE69717447D1 (de) | 2003-01-09 |
| DE69716104T2 (de) | 2003-05-28 |
| WO1997049409A1 (en) | 1997-12-31 |
| AU720570B2 (en) | 2000-06-08 |
| ATE225178T1 (de) | 2002-10-15 |
| CA2259150A1 (en) | 1997-12-31 |
| JP2000513351A (ja) | 2000-10-10 |
| CN1228694A (zh) | 1999-09-15 |
| NO985916L (no) | 1999-01-25 |
| JP4359651B2 (ja) | 2009-11-04 |
| BR9709942A (pt) | 1999-08-10 |
| JP2000514044A (ja) | 2000-10-24 |
| CN1228703A (zh) | 1999-09-15 |
| WO1997049390A1 (en) | 1997-12-31 |
| US6147094A (en) | 2000-11-14 |
| CA2258299A1 (en) | 1997-12-31 |
| AU720621B2 (en) | 2000-06-08 |
| AU3268997A (en) | 1998-01-14 |
| JP4162263B2 (ja) | 2008-10-08 |
| DE69716104D1 (de) | 2002-11-07 |
| EP0936915A1 (en) | 1999-08-25 |
| NO985916D0 (no) | 1998-12-17 |
| NZ333315A (en) | 2000-07-28 |
| EP0910360A1 (en) | 1999-04-28 |
| AU3268897A (en) | 1998-01-14 |
| EP0910360B1 (en) | 2002-11-27 |
| NO985917L (no) | 1999-01-25 |
| US6258828B1 (en) | 2001-07-10 |
| NO985917D0 (no) | 1998-12-17 |
| NZ333357A (en) | 2000-08-25 |
| EP0936915B1 (en) | 2002-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE228361T1 (de) | Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen | |
| DE69703294D1 (de) | Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten | |
| PT960107E (pt) | Compostos de paclitaxel 6-tio-substituidos | |
| DE69708100D1 (de) | Konjugate von cis-docosahexaensäure und paclitaxel | |
| DZ2614A1 (fr) | Compositions pharmaceutiques topiques contenant des dérivés de résorcinol. | |
| EP0911039A3 (en) | Drug-resin complexes stabilized by chelating agents | |
| ES2181744T3 (es) | Hidratos de paclitaxel cristalinos. | |
| BR9912327A (pt) | Inibidores da uroquinase | |
| PT1109571E (pt) | Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos | |
| MX9601994A (es) | Profarmacos de derivados de paclitaxel. | |
| WO1996041627A3 (en) | Iron compounds, compositions, methods of making the same and uses thereof | |
| MXPA02005045A (es) | Preparaciones farmaceuticas que contiene agentes citostaticos y aceptores de electrones para el tratamiento de cancer. | |
| AU8851298A (en) | L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof | |
| DK1135169T3 (da) | Anvendelse af et farmaceutisk præparat indeholdende et anticancermiddel og mindst et peptid. | |
| DE69818492D1 (en) | 7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele | |
| DK0777498T3 (da) | Konjugater fremstillet af metalkomplekser og oligonucleotider | |
| EA200100353A1 (ru) | Применение производного антрациклина для лечения опухоли печени | |
| WO2002038566A3 (en) | Carbene porphyrins and carbene porphyrinoids for use in medical diagnosis and treatment | |
| WO2001000189A3 (de) | Kombination von mtp-inhibitoren und stoffwechselbeeinflussenden wirkstoffen und ihre verwendung in arzneimitteln | |
| ES2195922T3 (es) | Composicion sinergica que comprende derivados de daunorrubicina y compuestos antimetabolitos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |